- Home
- SLS
as 10-28-2025 1:56am EST
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.
| Founded: | 2012 | Country: | United States |
| Employees: | N/A | City: | NEW YORK |
| Market Cap: | 238.7M | IPO Year: | N/A |
| Target Price: | $7.00 | AVG Volume (30 days): | 4.7M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.32 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.77 - $2.48 | Next Earning Date: | 11-12-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest SELLAS Life Sciences Group Inc. News
SLS Breaking Stock News: Dive into SLS Ticker-Specific Updates for Smart Investing
GlobeNewswire
6 days ago
SELLAS Life Sciences to Participate in the J.P. Morgan U.S. Opportunities Forum
GlobeNewswire
15 days ago
SELLAS Life Sciences to Present In Vivo Preclinical Data Demonstrating Statistically Significant Survival Benefit of SLS009 in T-Cell Prolymphocytic Leukemia at the European Society for Medical Oncology (ESMO) Congress 2025
Clinical Trials Arena
3 months ago
SELLAS’ CDK9 inhibitor to advance after “exceeding expectations” in AML
MT Newswires
3 months ago
Sellas Life Sciences Meets Primary Endpoints in Mid-Stage SLS009 Trial
GlobeNewswire
3 months ago
SELLAS Meets All Primary Endpoints in Phase 2 Trial of SLS009 in r/r AML and Receives FDA Guidance to Advance into First-Line Therapy Study
GlobeNewswire
4 months ago
SELLAS Life Sciences to be Added to Russell 3000® and Russell 2000® Indexes
Simply Wall St.
4 months ago
We Think SELLAS Life Sciences Group (NASDAQ:SLS) Needs To Drive Business Growth Carefully
GlobeNewswire
5 months ago
SELLAS Life Sciences Expands Scientific Advisory Board with Addition of Two World-Renowned Hematology and Oncology Experts
Compare SLS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SLS SELLAS Life Sciences Group Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.